|
業務類別
|
Biotechnology |
|
業務概覽
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others. |
| 公司地址
| 40 Guest Street, Boston, MA, USA, 02135 |
| 電話號碼
| +1 617 949-2680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cuebiopharma.com |
| 員工數量
| 29 |
| Ms. Lucinda Warren |
Interim President, Chief Executive Officer, Chief Financial and Business Officer |
美元 469.95K |
27/03/2026 |
| Dr. Daniel G. Baker, M.D.,PhD |
Interim Chief Development Officer |
-- |
16/03/2026 |
| Mr. Colin G. Sandercock |
Senior Vice President, General Counsel and Secretary |
美元 448.65K |
16/03/2026 |
|
|
| Dr. Pasha Sarraf, M.D.,PhD |
Chairman of the Board |
16/03/2026 |
| Mr. Patrick Verheyen |
Independent Director |
16/03/2026 |
| Ms. Jill M. Broadfoot |
Independent Director |
16/03/2026 |
| Dr. Frank Morich, M.D.,PhD |
Independent Director |
16/03/2026 |
| Dr. Peter A. Kiener, D.Phil. |
Independent Director |
16/03/2026 |
| Ms. Pamela D. Garzone |
Independent Director |
16/03/2026 |
|
|
|
|
